Integer Holdings Business Summary

Integer Holdings Corporation (ITGR) operates as a premier medical device contract development and manufacturing organization (CDMO), generating revenue through the design and production of high-end medical components and systems for original equipment manufacturers (OEMs). The company’s business is structured into three primary segments: Cardio & Vascular (C&V), which contributes approximately 60% of total revenue; Cardiac Rhythm Management & Neuromodulation (CRM&N), representing roughly 36%; and Other Markets, which serves the energy and military sectors following the company’s strategic exit from the Portable Medical business in early 2026. Integer occupies a critical niche in the global healthcare supply chain, competing with major medical technology firms such as Medtronic, Abbott Laboratories, Boston Scientific, and Stryker. While these entities are frequently customers, Integer distinguishes itself as a specialized, large-scale outsourcing partner providing end-to-end R&D and manufacturing capabilities that smaller, niche CDMOs cannot replicate. The leadership team is headed by President and CEO Payman Khales, who assumed the role in October 2025 after serving as the company’s Chief Operating Officer and President of the Cardio & Vascular segment. Khales, an alumnus of École Polytechnique de Montréal and Indiana University, brings extensive industrial leadership experience from previous roles at CECO Environmental and Ingersoll Rand. He is supported by Executive Vice President and CFO Diron Smith, a finance veteran with a 30-year pedigree including senior roles at Tiffany & Co. and GE. The company’s legacy is rooted in the work of founder Wilson Greatbatch, the inventor of the first successful internal pacemaker battery. Recent governance shifts include the March 2026 appointment of independent directors James Flanagan, former COO of PwC, and Aaron Kapito of Politan Capital Management, following a cooperation agreement with activist investor Irenic Capital Management.